The patient population receiving CD30 CAR-T differs substantially from those receiving CD19 CAR-T, as Hodgkin lymphoma tends to affect younger patients who receive less cytotoxic chemotherapy and more antibody–drug conjugate or immunotherapy-based treatments [18, 19]. The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.